Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis

摘要: Some medications have been shown to produce reductions in hs-CRP levels after initiating therapy. Whereas the role of renin-angiotensin system inflammatory process has documented more detail during last few years, impact an ACE-inhibitor therapy on this not fully understood so far. The aim study was investigate effect a with angiotensin-converting enzyme (ACE) inhibitor ramipril plasma concentrations patients atherosclerosis. A total 24 were enrolled prospective, uncontrolled, open-label multicenter study. Inclusion criteria atherosclerosis, baseline high-sensitivity C-reactive protein between 3 and 12 mg/l, LDL-Cholesterol ≤150 mg/dl no previous treatment ACE inhibitors or angiotensin receptor blockers. Ten patients, pretreated statins, 10 previously treated statins eligible for statistical analysis. Baseline significantly decreased from 3.99±1.61 mg/l (mean±SD) 2.72±1.19 (–32%) months mg daily (p=0.0002). decrease pronounced who had (–1.50 mg/l±1.44 mg/l) compared those (–0.90 mg/l±0.93 mg/l). administered dose atherosclerosis reduces concentration. This may contribute cardiovascular risk reduction mediated by aside blood pressure lowering effect.